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IN the latter part of March, 1965, supplies of two derivatives of Podophyllo-
toxin (SPG and SPI) were made available to us through the courtesy of Sandoz
(India) Ltd. From April to November, 1965, inclusive, we have treated 16
patients with one or both of these drugs. While these drugs have been used in
significant numbers of cases both in Europe and in the United States, no reports
of their efficacy in cancer patients in India are as yet available. The present
paper is a preliminary assessment of the results obtained and of some problems
encountered.
Chemistry and pharmacology.-Podophyllum has been extensively used in the
past for its anthelmintic and antiemetic action. It was also known to be effective
in viral papillomas and in Condyloma acuminata. SPI is podophyllic acid
ethylhydrazide. It is not absorbed through the intestinal mucosa. Parenterally
administered doses are excreted through the kidneys. SPG contains the purified
benzylidene compounds of the total glucosides of Podophyllum emodi-the prin-
cipal constituent being podophyllotoxin-,/-D-benzylidene glucoside. SPG can
only be given orally and on absorption is excreted through the bile. Both these
preparations are spindle-poisons, i.e. inhibit mitotic cell-division.
MATERIALS AND METHODS
SPI solution for )arenteral use was made available to us in 200 mg. ampoules.
Multiples of 200 mg. were therefore given daily-the quantity varying from
400 mg. to 1000 mg. per day. SPG was available in capsules containing 25 mg.
each. Either 2, 4, 6 or 8 capsules (50 to 200 mg.) per day were prescribed. SPG
solution for oral use or SPG jelly for topical application were not available to us
during the period with which this report is concerned. Patients with dysphagia
were asked to break open the SPG capsules and swallow the contents after mixing
with honev.
Every patient treated had h-iistologically proven malignant disease. Intra-
venous administration of SPI was done only after hospitalisation (except in one
patient who was admitted for a short period at another hospital but was regularly
observed by us). Oral medication was carried out on outpatient basis though
each patient was observed frequently (usually at weekly intervals never less
often than once every 4 weeks). All clinical observations were recorded by the
same observer (R. (C. C.) and all histopathologic and haematologic studies were
done bv the same pathologist (S. K. S.).34 R. C. CHAKRAVORTY, S. K. SARKAR, S. SEN AND B. MUKERJI
The 16 patients treated with Podophyllum derivatives can be divided broadly
into three groups:
I. Six patients were thought to be unfit for either surgery or radiationi at the
initial examination. The drug was therefore used as the primary therapeutic
modality.
II. Seven patients had been treated previously either surgically and/or by
radiation and had subsequently developed metastases.
III. Three patients had previously been treated by some other anticancer
chemotherapeutic drug but had either shown no response or had a relapse.
The histological types of cancers treated were as follows : haemangioperi-
cytoma, Ewing's tumour, osteogenic sarcoma, ovarian adenocarcinoma, mammary
adenocarcinoma, squamous carcinoma of the lung, squamous carcinoma of
pharynx, squamous carcinoma of larynx, squamous carcinoma of the gingiva,
mucoepidermoid salivary carcinoma, adenocarcinoma of the gastro-oesophageal
junction (one case of each type) and squamous carcinoma of the thoracic oeso-
phagus (5 cases).
The routes of administration in these 16 patients were as follows
Intra-arterial: 3 (2 femoral, I superior thyroid).
Intravenous: 10.
Oral: 13 (10 with initial intravenous therapy, 3 only orally).
The maximum daily dose with oral capsules was 200 mg.
The maximum parenteral daily dose (either intra-arterially or intravenously)
was 1000 mg. SPI is relatively stable at room temperatures. We therefore
thought that a slow rate of administration would decrease excretion in the
unchanged form and also lessen the possibility of side-effects. The intravenous
dose was given by dissolving 400 mg. of SPI in 500 ml. isotoInic glucose the
amount being run in over a period of approximately 90 minutes; a 1000 mg. dose
thus took about 3 hours when given intravenously. The intra-arterial dose was
given by gravity infusion over 24 hours-the drug was dissolved in 2 to 4 bottles
of isotonic glucose.
The average daily dose for the entire series varied between 827 mg. and 83 mg.
The average daily dose per kg. body-weight varied between 2-4 mg. and 25 S mg.
The maximum daily dose per kg. body-weight varied between 28-5 mg. and
3-2 mg.
RESULTS
Every patient in this series has been followed up to date. Objective results
were classified as follows:
(a) Regression objective diminution of tumour size persists for at least
3 months.
(b) Arrest progression of disease arrested or there is objective regression. but
duration of benefit is less than 3 months.
(c) None-disease progresses in the face of treatment.
This classification is not satisfactory but has the great advantage of simplicity.
It intentionally overlooks subjective relief as that cannot be mensurated. Sub-
jective relief is however a signal criterion of the efficacy of any anticancer chemo-
therapeutic drug. Only advanced cases of cancer beyond the scope of treatmentANTICANCER PODOPHYLLUM DERIVATIVES
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with conventional modalities are presently accepted for chemotherapy. Any
drug or measure that can offer relief to these patients deserves a place in our
armamentarium whether there be significant objective regression or not. The
Podophyllum derivatives were found to be of occasional striking benefit on this
count. Pain, when a severe symptom, disappeared early in most cases. Root
pain due to peri-oesophageal and paravertebral extension of oesophageal cancer
was alleviated or disappeared in most patients. Relief of dysphagia, if main-
tained, was considered as objective improvement. The patient with generalised
carcinomatosis from an ovarian primary was admitted with severe vomiting,
pelvic and thigh pain and respiratory distress. After 800mg. of SPI intra-
venously over two days her symptomatic improvement was dramatic. Relevant
data about the 16 patients studied are summarised in tabular form in Tables I,
II and III.
From the above data it will be seen that there were 3 regressions in the entire
series (about 17%). In every patient where pain was a distressing symptom
analgesia was noted soon after beginning of therapy except in patients 6 (Table I)
and 1 (Table TI). Patient 3 (Table I) had intra-arterial infusion into the left
femoral artery and complained of burning sensation when the infusate contained
SPI. After the third day (1-2 g. ofSPI) pain at the site ofher disease disappeared
and the previous paraesthesia also subsided gradually.
In some patients (4, Table I; 5 and 6, Table II) disease could be seen to progress
even while there was significant symptomatic relief. Indeed in a patient with
ovarian adenocarcinomatosis (Table III) there was dramatic symptomatic improve-
ment as mentioned before and the patient expired 3 weeks after discharge from
hospital.
At the outset the drug was given without any selection. Subsequently we
have decided to systematise the study and these drugs are now being used in
specific types of cancer. There are thus 6 patients with oesophageal primaries
available for study in this series (adenocarcinoma-1, squamous carcinoma-5).
Four of the 6 patients had dysphagia; improvement in swallowing was noted in
all 4 and lasted for periods of 5 weeks and more. One patient (4, Table II) had
had an oesophago-coloplasty with radiation to the transected oesophageal stump
previously. His main complaints were streaky haemoptysis and cough and the
characteristic radicular pain of peri-oesophageal vertebral spread. Both of these
were relieved for about 8 weeks on commencement of therapy with SPI/SPG.
Subsequently the symptoms recurred and progressed in spite ofcontinued therapy.
Cases 2 (Table I) and 2 (Table II) have had dramatic and persistent relief of
dysphagia even when there was evident reactivation of disease following radiation
therapy. Indeed, in case 2 (Table II) there was radiological evidence of some
relief of obstruction.
Cases 4, 5 and 6 (Table I), 1, 2 and 6 (Table II), 2 and 3 (Table III) (8 patients)
are already dead and cases 4, 5 and 7 (Table II) (3 patients) are known to be dying
of disease. The terminal phenomena in some of these patients deserve further
study.
Case 6 (Table I) was a 41 year old Nepalese male first seen with a huge left
lower gingival carcinoma with intra-oral fungation, involvement of the mandible
and large fixed left upper neck nodes. He was considered to be unfit for either
surgical excision or radiation therapy. It was therefore decided to treat him by
chemotherapy. Under local anaesthesia a polythene catheter was inserted into
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the left external carotid artery through the proximal stump ofthe divided superior
thyroid artery. 400 mg. of SPI were given daily through this catheter after
solution in isotonic glucose as mentioned earlier. There seemed to be some
increase in the pre-existing facial oedema and the patient started to complain of
intense left-sided hemicrania from the second day. This latter symptom passed
offspontaneously over the next 48 hours. The dose ofSPI was gradually increased
till he received 1000 mg. on the fifth day this was apparently well tolerated.
On the fourth and fifth days of intra-arterial administration his temperature went
up to 39.50 C. but responded to the exhibition of antibiotics. On the sixth day,
after 750 mg. (of a dose of 1000 mg.) of SPI had gone in, the patient complained
ofvery severe headache, he became extremely violent and his temperature shot up
to 40.50 C. It was observed that his breathing was laboured. A tracheostomy
was done though the tracheo-bronchial tree seemed to be reasonably dry. Paral-
dehyde was given intramuscularly to control the restlessness. At the beginning
ofthis acute episode the pupils were found to be dilated- theygradually contracted
however and became pin-point. All reflexes were grossly exaggerated with the
Babinski sign positive on both sides. The blood-pressure now fell rapidly after an
initial rise. The respiratory distress persisted in spite of oxygen given intra-
tracheally. The neck was rigid from the start of the episode but because of the
maniacal violence in spite of sedation lumbar puncture could not be performed.
The patient expired about 3 hours after the onset of the episode. Permission for
autopsy was not granted. We cannot postulate the cause of this acute episode
though the clinical features were suggestive of subarachnoid and/or pontine
haemorrhage. In the absence of post mortem examination, the possibility of SPI
going into the internal carotid artery and causing cerebral irritation can also not
be ruled out.
The terminal phase in patients 2 and 4 (Table I) and 2 and 3 (Table II) also
deserve mention. These patients gradually became weak without any specific
clinically recognisable lesion. The progressive weakness almost suggested
adrenal exhaustion, but administration ofcorticosteroids did nothing to ameliorate
the clinical worsening. Blood transfusions given as and when necessary from the
levels of the total r.b.c. count, the haemoglobin level and the packed cell volume
also failed to cause improvement. It seemed as if the patients had lost all desire
to live. In cases 2 (Table I) and 2 (Table II), both with oesophageal carcinoma,
there was near total relief of dysphagia, however the patients practically refused
to eat. This phenomenon needs further study.
Tolerance and side-effects
In this series the drugs were well tolerated at all dosage levels.
Four out of the 16 patients complained ofdiarrhoea. This started after about
2000 mg. of the drug had been received and in every instance was associated with
parenteral SPI. Frank diarrhoea was never seen in patients on oral SPG-
however, 3 patients who were chronically constipated previously were relieved of
their constipation while on therapy. Pyrexia (up to 40° C.) was observed in 2
patients having intra-arterial infusion and 3 patients on intravenous therapy.
It is not possible to opine whether this was infective or a direct effect of the drug.
One patient had severe hypotension on intravenous administration of SPI on each
of three occasions when this was attempted. Indeed, therapy had to be stopped
on each occasion. She subsequently showed no intolerance to oral SPG.ANTICANCER PODOPHYLLUM DERIVATIVES 39
These drugs proved to have relatively little effect on the haemogram. Bi-
weekly serial blood-counts showed little change in the total number of white cells
even at the highest dosage levels. In 7 patients the total white cell count went
up to around 12,000/c.mm. Four of these patients however had pyrexia as
described previously. In 7 patients the lymphocyte count went up by about
10% with a corresponding fall in the neutrophils. This was generally noted
around the third week of therapy. In another 2 to 3 weeks the relative propor-
tions reverted to near their original values. A progressive drop in the haemo-
globin value and the total r.b.c. count was seen in spite of energetic antianaemic
measures. This might be either an effect of the drug or of progressive disease.
The maximum daily dosage of 1000 mg. was given to 6 patients (31 3 mg./kg.,
28-5 mg./kg., 23*8 mg./kg., 30 mg./kg., 16 mg./kg. and 20 mg./kg.). This dose
caused severe fall in the blood-pressure in 1 patient on the fifth day, severe
diarrhoea in another and in a third was apparently well tolerated for 2 days but
on the third day produced severe cerebral irritation and death (see above).
In the latter part ofthis study we have added some other investigations to the
haematological studies. Only 6 patients have had these extra studies and do not,
in reality, fall within the purview of this paper. Briefly no significant changes
were noted in the following parameters before and after systemic therapy-Van
den Bergh test, bilirubin level, icteric index, alkaline phosphatase level, blood
ammonia and bone-marrow examination. These findings in a larger group of
patients will be presented in a separate paper.
SUMMARY
The Podophyllum derivatives SPI and SPG were used in 16 Indian patients
with far-advanced malignant neoplasms deemed unfit for any conventional
therapeutic modality.
The drugs were well tolerated at all dosage levels and caused relatively few
toxic effects except diarrhoea and occasional hypotension. One patient on
intracarotid infusion died while on therapy-the exact cause could not be
established.
Subjective improvement was remarkable in most cases-specially when pain
was an important feature. Objective regression was noted in 3 cases (more than
3 months). Dysphagia was relieved in most patients with carcinoma of the
oesophagus.